In a report released yesterday, David Roman from Goldman Sachs maintained a Buy rating on Baxter International (BAX – Research Report), with a price target of $37.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
David Roman has given his Buy rating due to a combination of factors that suggest Baxter International is poised for growth. The company has taken a conservative approach to its sales guidance for the second quarter of 2025, but the overall performance for the first half of the year aligns with expectations. Despite some fluctuations, the outlook for 2025 indicates that potential growth drivers are likely to outweigh risks, leading to mid-single-digit percentage growth in revenue.
Additionally, Baxter International’s strategic initiatives post-separation from Vantive are promising. The company is focusing on increasing research and development investments to foster innovation, streamlining operations to capitalize on growth opportunities, and reducing debt to enhance financial flexibility. These efforts are expected to contribute to improved operating margins and sustainable performance, supporting the Buy rating.